{
    "root": "2e77a034-b0ae-4694-8ac0-ae1319754d3a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Octreotide Acetate",
    "value": "20240730",
    "ingredients": [],
    "indications": "octreotide acetate injectable suspension 10 mg , 20 mg , 30 mg indicated patients initial treatment octreotide acetate injection shown effective tolerated .",
    "contraindications": "octreotide acetate injectable suspension administered trained healthcare provider . important closely follow mixing instructions included packaging . octreotide acetate injectable suspension must administered immediately mixing . directly inject diluent without preparing suspension . recommended needle size octreotide acetate injectable suspension 1½ ” 19 gauge safety injection needle ( supplied product kit ) . patients greater skin muscle depth , size 2 ” 19 gauge needle ( supplied ) may used . octreotide acetate injectable suspension administered intramuscularly ( im ) gluteal region 4-week intervals . octreotide acetate injectable suspension intervals greater 4 weeks recommended . injection sites rotated systematic manner avoid irritation . deltoid injections avoided due significant discomfort injection site given area . octreotide acetate injectable suspension never administered intravenously subcutaneously . following regimens recommended .",
    "warningsAndPrecautions": "octreotide acetate injectable suspension available single-dose kits containing 8-ml single-dose vial 10 mg , 20 mg , 30 mg strength , prefilled syringe containing 2 ml diluent , one vial adapter , one sterile 1 1/2 ” 19 gauge safety injection needle . instruction booklet preparation suspension injection also included kit . product kits 10 mg kit ……………………… . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 0480‐9257‐08 20 mg kit ……………………… . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 0480‐9259‐08 30 mg kit ……………………… . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 0480‐9262‐08 prolonged storage , octreotide acetate injectable suspension stored refrigerated temperatures 2°c 8°c ( 36°f 46°f ) protected light time . octreotide acetate injectable suspension product kit remain room temperature 30 60 minutes prior preparation suspension . however , preparation suspension must administered immediately .",
    "adverseReactions": "none .",
    "indications_original": "Octreotide acetate for injectable suspension 10 mg, 20 mg, and 30 mg is indicated in patients in whom initial treatment with octreotide acetate injection has been shown to be effective and tolerated.",
    "contraindications_original": "Octreotide acetate for injectable suspension should be administered by a trained healthcare provider. It is important to closely follow the mixing instructions included in the packaging. Octreotide acetate for injectable suspension must be administered immediately after mixing.\n                     \n                        Do not directly inject diluent without preparing suspension.\n                     \n                     The recommended needle size for administration of octreotide acetate for injectable suspension is the 1½” 19 gauge safety injection needle (supplied in the drug product kit). For patients with a greater skin to muscle depth, a size 2” 19 gauge needle (not supplied) may be used.\n                     Octreotide acetate for injectable suspension should be administered intramuscularly (IM) in the gluteal region at 4-week intervals. Administration of octreotide acetate for injectable suspension at intervals greater than 4 weeks is not recommended.\n                     Injection sites should be rotated in a systematic manner to avoid irritation. Deltoid injections should be avoided due to significant discomfort at the injection site when given in that area.\n                     \n                        Octreotide acetate for injectable suspension should never be administered intravenously or subcutaneously.\n                     \n                  \n                  The following dosage regimens are recommended.",
    "warningsAndPrecautions_original": "Octreotide acetate for injectable suspension is available in single-dose kits containing an 8-mL single-dose vial of 10 mg, 20 mg, or 30 mg strength, a prefilled syringe containing 2 mL of diluent, one vial adapter, and one sterile 1 1/2” 19 gauge safety injection needle. An instruction booklet for the preparation of drug suspension for injection is also included with each kit.\n                  \n                     \n                     \n                        \n                           \n                              \n                                 Drug Product Kits\n                              \n                           \n                        \n                        \n                           \n                              10 mg kit ………………………......................................NDC  0480‐9257‐08\n                           \n                        \n                        \n                           \n                              20 mg kit ………………………......................................NDC  0480‐9259‐08\n                           \n                        \n                        \n                           \n                              30 mg kit ………………………......................................NDC  0480‐9262‐08\n                           \n                        \n                     \n                  \n                  For prolonged storage, octreotide acetate for injectable suspension should be stored at refrigerated temperatures between 2°C to 8°C (36°F to 46°F) and protected from light until the time of use. Octreotide acetate for injectable suspension drug product kit should remain at room temperature for 30 to 60 minutes prior to preparation of the drug suspension. However, after preparation the drug suspension must be administered immediately.",
    "adverseReactions_original": "None."
}